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Abstract
Roughly forty-three children are diagnosed with cancer daily.. Approximately 1190 children
are expected to die from pediatric cancer this year in the United States alone—as the disease is the
leading cause of death in children and adolescents, ages 1U14, in the country.
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I. INTRODUCTION
Roughly forty-three children are diagnosed with cancer daily.1
Approximately 1190 children are expected to die from pediatric cancer this
year in the United States alone—as the disease is the leading cause of death
in children and adolescents, ages 1U14, in the country.2 More than 40,000
children suffer through cancer treatment every year and, to add insult to
injury, roughly 15,700 more children will be diagnosed with pediatric cancer
this year alone.3 A child of any age, ethnicity, gender, or socio-economic
group can fall victim to a pediatric cancer diagnosis.4
Despite leading to the most disease-related deaths among children,
along with encouraging advances in the entire cancer research field, children
usually are not the recipients of the new and promising drugs and treatments
resulting from those advancements.5 This stems from the rarity of pediatric
cancers, which represents less than one percent of newly diagnosed cancers
each year in the United States.6 In turn, with comparatively fewer patients,
the pediatric cancer market does not offer enough return for pharmaceutical
companies to invest in developing and testing drugs specifically designed to
target pediatric cancers.7 Peter C. Adamson, M.D., who is the Chair of the
* First and foremost, Nicholas M. Fiorello dedicates this Comment in loving
memory of his brother, Adam Fiorello, who unfortunately lost his battle to Alveolar
>PonV03j0+o,W03of o ,o,T .TVOo*,OW Wo1WT,e XOWP0Lo+ To,1TV PO+ "oWPTL0,8+ O1
Environmental Science at Florida State University. He is currently a Juris Doctor Candidate
for May 2019 at Nova Southeastern University, Shepard Broad College of Law. Nicholas
would like to thank his parents, Heidi and Michael Fiorello, for their unconditional love,
support, and instilling the importance of hard work and the necessity of passion at an early
age. He would also like to thank his friends and professors for constantly pushing him beyond
his limits and positively influencing his legal education. Lastly, Nicholas would like to
graciously thank his fellow colleagues of Nova Law Review, Volume 42, for the hard work,
dedication, and time spent refining and perfecting this Comment.
1. Geoff Duncan, Childhood Cancer Statistics, CURESEARCH,
http://curesearch.org/Childhood-Cancer-Statistics (last modified Aug. 5, 2016).
2. Childhood Cancers, NAT8L CANCER INST.,
http://www.cancer.gov/types/childhood-cancers (last updated Aug. 30, 2017).
3. Duncan, supra note 1. Twelve percent of the children diagnosed with
cancer this year will not survive. Id.
4. Id.
5. See Duncan, supra note 1; KIDS V CANCER, RESEARCH TO ACCELERATE
CURES AND EQUITY FOR CHILDREN ACT (2017), http://www.kidsvcancer.org/wp-
content/uploads/2017/03/RACE-for-Children-Act-ONE-PAGER-.pdf.
6. Childhood Cancers Research, NAT8L CANCER INST.,
http://www.cancer.gov/research/areas/childhood (last updated Mar. 1, 2018).
7. Peter C. Adamson et al., Drug Discovery in Paediatric Oncology:
Roadblocks to Progress, 11 NATURE REVS. CLINICAL ONCOLOGY 732, 732 (2014); see also
Holly Fernandez Lynch, Give Them What They Want? The Permissibility of Pediatric
2
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!POLV,T18+ A1W0L0Qj `,0). hR!A`<gf Po+ O1ST,,TV .0*T1*OoL 1TQLOQT1WT nj
the pharmaceutical companies which continue to brush off the need of
pediatric cancer research.8
The lack of internal incentives within the pharmaceutical industry
entice companies to spend valuable money and time on pediatric research
which has left children to be treated as miniature adults, when, in reality,
they differ immensely.9 The vast differences from adults have led to an
individualized medical specialty solely dedicated to children called
pediatrics.10 R@TVOo*,OW 01W0L0Qj O+ o 3TVOWoL +.TWOoL*j S0W)+TV 01 *PT Wo,T
0S WPOLV,T1 mO*P Wo1WT,f<11 and has evolved in less than sixty years into its
own medical sub-specialty.12 The pharmaceutical industry has disregarded
the differences between children and adults, leaving children to be treated
with medication either only approved for or only tested on adults.13 Pediatric
doctors are forced to prescribe children off-label medications that have only
been approved for use in adults.14 These physicians must estimate
appropriate, weaker doses for their child patients based on dosages found to
nT +oST O1 oV)L*+f )+)oLLj )+O1Q *PT WPOLV8+ mTOQP* o+ *PT no,03T*T, S0,
comparison.15 Although this practice is custom within the field, off-label use
Placebo-Controlled Trials Under the Best Pharmaceuticals for Children Act, 16 ANNALS
HEALTH L. 79, 79 (2007).
8. Adamson et al., supra note 7, at 732U33.
In the [United States], approximately 60% of funding for biomedical research stems
from the private biopharmaceutical sector. The next largest funder is the [National
^1+*O*)*T 0S _ToL*P hRX^_<gpf mPOWP +)..0,*+ o..,0kO3o*TLj JG2 0S ,T+To,WPe a0,
childhood cancers, however, which represent a constellation of more than 100 rare
and ultra-rare diseases, the biopharmaceutical sector has an almost negligible
investment, resulting in virtually all research funding emanating from the National
!o1WT, ^1+*O*)*T hRX!^<gf .,O(o*T S0)1Vo*O01+f o1V .POLo1*P,0.OW +0),WT+e ;PO+
limitation of funding and investment from industry impacts all key areas of drug
development, spanning target discovery through clinical development.
Id. at 732 (footnote omitted).
9. Fernandez Lynch, supra 10*T Ef o* ECe RtT+.O*T *PTO, +O3OLo, o..To,o1WT,
children are not just miniature adults. They experience different thought processes, are given
VOSST,T1* LTQoL ,OQP*+f o1V ,T+.01+OnOLO*OT+ e e e e< Id. (footnote omitted).
10. Id.
11. Childhood Cancers, supra note 2.
12. Adamson et al., supra note 7, at 733.
13. Fernandez Lynch, supra note 7, at 82; Lisa Jerles, Note, The Best
Pharmaceuticals for Children Act and the Pediatric Research Equity ActBHelping or Hurting
48erica’s 2hiP$ren6, 6 CARDOZO PUB. L. POL8Y&ETHICS J. 515, 51617 (2008).
14. Jerles, supra note 13, at 517; see also Fernandez Lynch, supra note 7, at
82U83.
15. S. Rep. No. 105-43, at 51 (1997); Fernandez Lynch, supra note 7, at 83;
see also Jerles, supra note 13, at 516; Zoe Read, Our Disproportionate Focus on Adult Over
Pediatric Cancer Research, ATLANTIC: HEALTH (Jan. 2, 2013),
http://www.theatlantic.com/health/archive/2013/01/our-disproportionate-focus-on-adult-over-
pediatric-cancer-research/266684/.
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of medications can be dangerous, or at the very least ineffective on pediatric
patients, due to the uncertainty of particular estimates.16 This uncertainty
may lead physicians to potentially withhold certain medicines that could
have provided potential benefits to that child, leading to a possible
catastrophic result.17
Adults diagnosed with cancer may be comforted by the idea that
several different treatments may be available to them.18 On the other hand,
children—as well as their families—may not feel the same, as both clinical
trials and drugs are not a priority among companies that want to quickly
launch effective drugs into the market.19 Current drug development focuses
mainly on cancers that are close to, if not non-existent, in children such as
adult carcinomas.20
Since the early 1970s, the federal government has made a more
concerted effort to regulate the pediatric field and has attempted to improve
the efficacy and safety, as well as increase the number of pharmaceutical
drugs available specifically for children.21 Within the last ten to fifteen
years, the federal government has attempted to improve the market and make
more drugs available to treat children, especially through the 2002 Best
Pharmaceu*OWoL+ S0, !POLV,T1 #W* hR"@!#<g o1V *PT @TVOo*,OW >T+To,WP
b-)O*j #W* hR@>b#<g 0S JccIe22 These laws have been incrementally
successful, albeit with a limited positive impactf RLToVO1Q *0 P)1V,TV+ 0S V,)Q
16. S. Rep. No. 105-43, at 51; Fernandez Lynch, supra note 7, at 82U83; see
also I. Glenn Cohen, Therapeutic Orphans, Pediatric Victims? The Best Pharmaceuticals for
Children Act and Existing Pediatric Human Subject Protection, 58 FOOD & DRUG L.J. 661,
662 (2003).
17. Lynch, supra note 7, at 83.
18. Cures for All: US Lawmakers Should Give Drug Firms the Confidence to
Test Cancer Therapies in Children, 535 NATURE INT8L WKLY. J. SCI. 465, 465 (2016),
http://www.nature.com/polopoly_fs/1.20331!/menu/main/topColumns/topLeftColumn/pdf/53
5465b.pdf.
19. Id.
20. Adamson et al., supra note 7, at 732.
21. Jerles, supra note 13, at 515; see also Lauren Hammer Breslow, Note, The
Best Pharmaceuticals for Children Act of 2002: The Rise of the Voluntary Incentive Structure
and Congressional Refusal to Require Pediatric Testing, 40 HARV. J. ON LEGIS. 133, 135U36
(2003).
22. Jerles, supra note 13, at 515U16; Fernandez Lynch, supra note 7, at 94U
95; Cures for All: US Lawmakers Should Give Drug Firms the Confidence to Test Cancer
Therapies in Children, supra note 18, at 466; see also Best Pharmaceuticals for Children Act
of 2002, Pub. L. No. 107-109, § 1, 115 Stat. 1408, 1408 (codified as amended in scattered
sections of 21 U.S.C.); Pediatric Research Equity Act of 2003, Pub. L. No. 108-155, § 1, 117
Stat. 1936, 1936 (codified as amended in scattered sections of 21 U.S.C.).
4
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labels being updated with information for use in cPOLV,T1e<23 But despite the
limited positive impact in terms of the entire pediatric pharmaceutical field,
there are still not enough drugs being evaluated in children battling cancer
and, due to legal loopholes, children fighting cancer have been prevented
from access to promising new drugs.24 In response to the modest success of
these prior laws, legislation is now attempting to eliminate those exemptions
and loopholes to increase opportunities for drug development and change the
pediatric cancer landscape for the better.25
The PREA and the BPCA both were enacted roughly fifteen years
ago during a time when drugs were developed to fight specific types of
cancers in certain parts of the body.26 One barrier to drug development
breakthroughs, specifically for pediatric cancer, stands out plain and
simple—Radults do not develop pediatric cancers.<27 Additionally, methods
for drug development have changed in oncology.28 Instead of targeting
specific types of cancers, advances in cancer research have led to drugs being
developed through molecular targeting.29 Using the exceptions in PREA,
companies can get a waiver from the Food and Drug Administration
hRat#<gf mPOWP V0T+ 10* ,T-)O,T W01V)W*O1Q .TVOo*,OW +*)VOT+ S0, *PTO, V,)Q+f
thus preventing children with cancer from accessing new drugs.30 New
legislation originally proposed to Congress in 2016—and was reintroduced
February 27, 2017—will end those exceptions, thus not awarding more
waivers to pharmaceutical companies.31 This legislation is called the
23. Adamson et al., supra note 7, at 737; Cures for All: US Lawmakers
Should Give Drug Firms the Confidence to Test Cancer Therapies in Children, supra note 18,
at 466.
24. Adamson et al., supra note 7, at 737; Cures for All: US Lawmakers
Should Give Drug Firms the Confidence to Test Cancer Therapies in Children, supra note 18,
at 466.
25. Cures for All: US Lawmakers Should Give Drug Firms the Confidence to
Test Cancer Therapies in Children, supra note 18, at 466; A RACE to the Finish!, CHILD.
CAUSE FOR CANCER ADVOC. (July 10, 2017), http://www.childrenscause.org/blog/2017/2/27/a-
bill-to-generate-more-treatments-for-childhood-cancer.
26. Rick Allen, Opinion, Race Is Now on to Pass the RACE for Children Act
to Beat Childhood Cancer, AUGUSTA CHRON. (Ga.), July 16, 2017, at E3; see also § 1, 115
Stat. at 1408; § 1, 117 Stat. at 1936.
27. Allen, supra note 26.
28. Id.
29. Id. The law has not changed or been updated to reflect scientific advances
and has thus stifled childhood cancer research and treatment. Id.
30. Cures for All: US Lawmakers Should Give Drug Firms the Confidence to
Test Cancer Therapies in Children, supra note 18, at 466; § 2(a), 117 Stat. at 1936U37.
31. Id.; Research to Accelerate Cures and Equity for Children Act, S. 456,
115th Cong. §§ 1U2 (as introduced in Senate, Feb. 27, 2017).
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Research to #WWTLT,o*T !),T+ o1V b-)O*j S0, !POLV,T1 #W* hR>#!b<ge32
RACE updates the 2003 PREA law to better correlate to advances in
medicine.33
This Comment will explain the current landscape of pediatric drug
development and how scientific advances have caused the need for
legislation throughout the past.34 Part II will discuss the history of children
in pediatric research and examine how history has influenced the current
landscape of pediatrics, especially within pediatric oncology.35 Part III will
discuss prior law, the influence of historical actions on the creation of these
laws, and how these laws have evolved and adapted since enactment.36 Part
IV will discuss the proposed new legislation and how it updates outdated
prior law to better reflect advances in modern medicine.37 Lastly, Part V will
offer a conclusion.38
II. CHILDREN INMEDICALRESEARCH: UNREGULATED RESEARCH TO
PARANOIA TOMODERNDAY
There is a long, dark history of abuses when it comes to pediatric
research, which have attached a negative connotation to the practice.39
Those abuses of children in medical experimentation caused concern in the
latter portion of the twentieth century, creating a protective attitude, which
has incidentally led to children being virtually excluded from research.40 But
the progress resulting from clinical research in pediatrics from the 1950s to
the late 1990s has contributed to a policy shift favoring participation of
children in medical studies.41 Additionally, the halted—or at best, slowed
32. S. 456 § 1. Also presented to the House of Representatives on the same
date as H.R. 1231. Id.
33. Michael McCaul et al., The Race to Fight Childhood Cancer, HILL (July
12, 2017, 2:30 PM), http://www.thehill.com/blogs/congress-blog/healthcare/341686-the-race-
to-fight-childhood-cancer.
34. See infra Parts IUIV.
35. See infra Part II.
36. See infra Part III.
37. See infra Part IV.
38. See infra Part V.
39. Breslow, supra note 21, at 135U36.
40. Fernandez Lynch, supra note 7, at 86; Michelle Oberman & Joel Frader,
Dying Children and Medical Research: Access to Clinical Trials as Benefit and Burden, 29
AM. J.L. &MED. 301, 301 (2003).
41. Oberman & Frader, supra note 40, at 302U04.
By the mid-1980s, the absence of effective treatment, much less cures, for Acquired
^33)1T tO+0,VT, =j1V,03T hR#^t=<g LTV oV(0Wo*T+ *0 VT3o1V oWWT++ *0 WLO1OWoL
*,OoL+ o,Q)O1Qf R# t,)Q ;,OoL O+ _ToL*P !o,T ;00e< ;PO+ Wo3.oOQ1 PTL.TV *0
transform the public perception of medical experimentation from a risky,
exploitative venture into the best response to an incurable disease.
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progress—of potentially valuable biomedical advances due to the many
regulations put in place to protect children, had led to many federal policy
changes towards the end of the 1990s.42 For example, in 1998, the FDA
mandated that the NHI supported Phase III clinical trials, which were to be
performed to include children, unless there was proper justification for an
exclusion.43 The general shift in American thinking in terms of including
WPOLV,T1 O1 3TVOWoL ,T+To,WP *T1V+ *0 QT* Poij ,TQo,VO1Q R.o,*OWO.o*O01 0S
children in Phase I clinicoL *,OoL+f mPOWP o,T O1*T1VTV *0 T+*onLO+Pf :*0kOWO*jf
3T*on0LO+3f on+0,.*O01f TLO3O1o*O01f o1V 0*PT, .Po,3oW0L0QOWoL oW*O01e8<44
Although conducting Phase I studies is necessary to benefit sick children in
the future, it does not have the necessary weight to solely justify medical
experimentation on children.45 But the evidence suggests that enrollment in
trials produces better outcomes compared to non-enrollment, as well as the
increased success in later phase trials have led to continued enrollment in
Phase I trials, despite the lasting moral dilemma.46
A. The Negative Connotation Attached to Pediatric Studies: The Result
of Historical Abuses
Due to an extensive list of historical abuses in research, children
have been protected from participation in medical research, thus limiting
medical advances in the field.47 With little advances in modern day pediatric
3TVOWO1Tf O1 W03.o,O+01 *0 *PT oV(o1WT+ O1 oV)L* 3TVOWO1Tf *PO+ R.,0*TW*O(T
o**O*)VT mT1* *00 So,e<48 Throughout history, children have been used in
medical testing because they were convenient and cheap subjects, as they
could not safeguard their own rights and interests.49 Before the twentieth
century, the legal status of a child was not the same as it is today.50 Children
Id. at 304 (footnote omitted).
42. Id. at 303.
43. Id.
44. Id. at 304U05 (quoting George J. Annas, Questing for Grails: Duplicity,
Betrayal and Self-Deception in Postmodern Medical Research, 12 J. CONTEMP. HEALTH L. &
POL8Y JCEf IKc hKCCFgge R;PT VT+OQ1 0S o @Po+T ^ +*)Vj QT1T,oLLj O1(0L(T+ .LoWO1Q
participants on escalating doses of a study drug and observing them to determine the
3okO3)3 V0+T o* mPOWP *PT V,)Q Wo1 +oSTLj nT *0LT,o*TVe< Oberman & Frader, supra note 40,
at 305.
45. Id. at 305.
46. See id. at 307U08.
47. Fernandez Lynch, supra note 7, at 86 & n.30.
48. Id. at 86; see also Read, supra note 15.
49. Lanie Friedman Ross & Catherine Walsh, Minority Children in Pediatric
Research, 29 AM. J.L. &MED. 319, 320 (2003).
50. See Breslow, supra note 21, at 136.
7
Fiorello: The Race Against The Clock: A New Bill Providing Hope For Childre
Published by NSUWorks, 2018
262 NOVA LAW REVIEW [Vol. 42
mT,T W01+OVT,TV RWPo**TLf .,0.T,*jf o1V Tk*T1+O01+ 0S *PTO, .o,T1*+e<51 Due to
the little recourse the law provided, children were legally unable to protect
their own interests, resulting in children being vulnerable to many cases of
what would currently be classified as abuse or abandonment.52
Many developments from medical testing were results of research
performed on orphans, institutionalized childrenf 0, T(T1 *PT .Pj+OWOo18+
own children.53 Physicians used the types of children mentioned previously
to develop vaccines for diseases, such as: Small pox, measles, tuberculosis,
scurvy, and rickets.54 These medical tests involved exposing children to
strands of these diseases after inoculation with a potential vaccine.55 To
determine the efficacy of surgical procedures and medical technology, such
as X-rays, physicians used children as experimental test subjects.56 Although
there was some minor backlash throughout history regarding the use of
medical experimentation on children, it was not until after World War II—
when the horrific experiments conducted by the Nazis had been publicized—
that there was a true focus on protections of research subjects in medical
experimentation.57 While the subsequent advances in the pediatric field
stemmed from medical experimentation and drug testing on children, their
vulnerability was exploited until regulations were put into place.58
B. Responses to Medical Abuse of Children
Public outrage, dated as far back as the 1870s, was a driving factor in
the creation of organizations to protect children.59 This led the medical
community to realize that the needs of children are different from those of
adults.60 In 1873, a separate division was created by the American Medical
#++0WOo*O01 hR#Y#<g *0 S0W)+ +0LTLj 01 m03T1 o1V WPOLV,T1e61 Despite the
growing outcry su..0,*O1Q WPOLV,T18+ ,OQP*+ o1V .,0*TW*O01+f *PT,T mo+ 10* o1
T1*O*j W,To*TV *Po* m0)LV .,030*T WPOLV,T18+ mTLSo,T )1*OL KCIc mPT1 *PT
independent American Academy of Pediatrics was founded.62 In addition to
children, other classes of people, including African Americans and the
51. Id.
52. Id.
53. Id. at 136U37.
54. Id. at 137.
55. Breslow, supra note 21, at 137.
56. Id. at 138.
57. See Cohen, supra note 16, at 673; Ross & Walsh, supra note 49, at 320.
58. Breslow, supra note 21, at 137.
59. Id. at 136.
60. Id.
61. Id. at 136U37.
62. Id. at 137.
8
Nova Law Review, Vol. 42, Iss. 2 [2018], Art. 4
https://nsuworks.nova.edu/nlr/vol42/iss2/4
2018] THE RACE AGAINST THE CLOCK 263
elderly, were subjected to medical experimentation due to their
vulnerability.63 Public exposure of the abuse occurring in the medical field
prompted enough backlash to fuel legal regulation of clinical studies.64
In response to the HoL0Wo)+* o1V *PT XoiO8+ 3TVOWoL .,oW*OWT+f oS*T,
World War II, the first international code establishing rights for human
,T+To,WP +)nNTW*+ mo+ W,To*TV o1V *O*LTV *PT X),T3nT,Q !0VT hR!0VT<ge65
The Code did not allow research on non-consenting persons, employing the
doctrine of informed consent, a principle still practiced today.66 Although by
this time it was established that children could not consent themselves, the
Code highlighted informed consent of competent individuals and not
incompetent subjects.67 It was not addressed until 1964, when the World
Medical Association published the Declaration of Helsinki, which included
guidelines for surrogate consent for those who could not consent
themselves.68 Although these international guidelines were established, they
were simply guidelines—lacking any legitimate legal authority to bind the
science community.69
Until the 1970s, the government did not take many steps towards
regulating pediatric testing, including not codifying any of the earlier
international guidelines published in years prior.70 In 1973, the federal
Q0(T,13T1* SO1oLLj ,T+.01VTV *0 WPOLV,T18+ 1TTV S0, WLO1OWoL .,0*TW*O01+ O1
3TVOWoL ,T+To,WP mPT1 R*PT tT.o,*3T1* 0S _ToL*Pf bV)Wo*O01f o1V 6TLSo,T—
10m *PT tT.o,*3T1* 0S _ToL*P o1V _)3o1 =T,(OWT+ hR__=<g<—issued new
rules on experimentation with human subjects.71 Children did not benefit
from these rules as a majority of the focus was placed on adult subjects.72
Responding to this lack of focus on children and to create legal standards for
testing in WPOLV,T1f R!01Q,T++ T1oW*TV *PT Xo*O01oL >T+To,WP #W*f mPOWP
[generated] the National Commission for the Protection of Human Subjects
0S "O03TVOWoL o1V "TPo(O0,oL >T+To,WP hRXo*O01oL !033O++O01<ge<73 But
63. Breslow, supra note 21, at 138.
64. Id.
65. Fernandez Lynch, supra note 7, at 98; Joanne Roman, Note, U.S. Medical
Research in the Developing World: Ignoring Nuremberg, 11 CORNELL J.L. & PUB. POL8Y 441,
448 (2002).
66. 45 C.F.R. § 46.116 (2016); Fernandez Lynch, supra note 7, at 98; Roman,
supra note 65, at 445, 448U49.
67. Fernandez Lynch, supra note 7, at 98.
68. Id.
69. Id.
70. See Breslow, supra note 21, at 138; Fernandez Lynch, supra note 7, at 98U
99.
71. Breslow, supra note 21, at 138; Fernandez Lynch, supra note 7, at 99.
72. Breslow, supra note 21, at 138.
73. Id.
9
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*PT Xo*O01oL !033O++O01 VOV 10* +)n3O* o1j R,TW033Tndations for pediatric
WLO1OWoL +*o1Vo,V+< S0, ,0)QPLj S0), jTo,+e74 The rules were finally published
in 1983 and created strict guidelines protecting child clinical subjects tested
in HHS funded research.75 The rules only applied to HHS funded research—
limiting the reach of legal authority.76 There was no change to the
o..LOWo*O01 0S *PT+T ,)LT+ )1*OL Jcccf *P,0)QP *PT !POLV,T18+ _ToL*P #W* 0S
2000, that Congress mandated the HHS to create rules for the general testing
of children, both in public and privately funded clinical studies.77
Following the history of abuse, federal regulations that were put into
place to safeguard children from similar harm have led to the current
landscape where pediatric testing and drugs developed solely for children are
virtually non-existent.78 In less than fifty years, clinical research in pediatric
oncology has made substantial progress against many forms of childhood
cancer.79 #L*P0)QP 0(T,oLL .,0Q,T++ Po+ nTT1 LO3O*TVf Rq+p)WP +)WWT++ 10
doubt contributed to a willingness to permit children to become the subjects
of medical experiments, and perhaps reflected a more general shift in
#3T,OWo1 *PO1MO1Q on0)* *PT 1o*),T 0S 3TVOWoL ,T+To,WPe<80 But due to
several factors, such as the strict regulations protecting children, the pediatric
field is much more complicated than working with adults—and
pharmaceutical companies could avoid the challenges of working with
pediatric patients by choosing not to perform pediatric studies.81 Actions like
these by pharmaceutical companies exempLOSj WPOLV,T18+ 1TTV S0, LTQO+Lo*O(T
action to be included in mainstream pharmaceutical research.82
t)T *0 .Po,3oWT)*OWoL W03.o1OT+8 TkWL)+O01 0S 3o,MT*O1Q 0,
labeling drugs for pediatric populations—leading to a lack of pediatric drugs
on the market—children have been labeled as therapeutic orphans, as they
are forced to use treatment designed for adults instead of treatments designed
for themselves.83 Pediatricians have been forced to treat children through
74. Id. at 139.
75. Id.
76. See id. at 139U40.
77. Breslow, supra note 21, at 139U40; see also 42 U.S.C. § 284 (2000).
78. Fernandez Lynch, supra note 7, at 86; Oberman & Frader, supra note 40,
at 301U02.
79. Oberman & Frader, supra 10*T Hcf o* IcJe R;PT 30+* W03301 S0,3 0S
childhood leukemia went from being a nearly always fatal disease to one cured more than
[75%] of the ti3Te< Id.
80. Id. R"TQO11O1Q O1 *PT 3OV-1980s, in response to scientific progress
achieved through clinical research in cancer and AIDS, Americans began to demand access to
WLO1OWoL *,OoL+e< Id.
81. Breslow, supra note 21, at 144; Lynch, supra note 7, at 86.
82. Breslow, supra note 21, at 144.
83. Id. at 145.
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.off-Pa9eP’ 7rescri9in" of medicines labeled for adults with the same or
similar condition.84 In an effort to improve drug labeling for pediatric use,
the FDA published a final rule in 1994, which did not require any new
testing, but required pharmaceutical companies to examine available drug
data on pediatric use.85 If information was found to support pediatric
labeling for the drug, then a condition required that company to file a
supplemental new drug application.86 In order to satisfy the pediatric
LonTLO1Q ,T-)O,T3T1*f *PO+ ,)LT oLL0mTV R.Po,3oWT)*OWal companies [to] use
adequate and well-controlled adult studies in addition to pharmacokinetic,
+oST*jf o1V .Po,3oW0Vj1o3OWq+p Vo*o< o+ +)..0,*e87 Despite an attempt to
change the landscape of pediatric medicine, this FDA initiative failed to
encourage pharmaceutical companies to conduct any pediatric research or
improve pediatric labeling.88
The failure of the 1994 voluntary rule led the FDA to publish a much
more stringent regulation in 1998, the Pediatric Rule hR@TVOo*,OW >)LT<g.89
This rule awarded the FDA with the authority to require pharmaceutical
companies to conduct pediatric studies on new and existing marketed
drugs.90 However, the Pediatric Rule was invalidated by a United States
district court in Association of American, Physicians & Surgeons v. FDA.91
;PT W0),* Q,o1*TV *PT .LoO1*OSS8+ 30*O01 S0, +)33o,j N)VQ3T1* o1V PTLV *Po*
*PT R@TVOo*,OW >)LT TkWTTVqTVp *PT at#8+ +*o*)*0,j o)*P0,O*je<92
84. Id.
85. Breslow, supra note 21, at 151U52; see also Specific Requirements on
!01*T1* o1V a0,3o* 0S ZonTLO1Q S0, _)3o1 @,T+W,O.*O01 t,)Q+& >T(O+O01 0S R@TVOo*,OW 9+T<
Subsection in the Labeling, 59 Fed. Reg. 64,240, 64,240 (1994) (codified as amended in 21
C.F.R. § 201 (2016)).
86. Specific Requirements on Content and Format of Labeling for Human
Prescription Drugs; Breslow, supra note 21, at 152; >T(O+O01 0S R@TVOo*,OW 9+T< =)n+TW*O01 O1
the Labeling, 59 Fed. Reg. at 64, 240.
87. Specific Requirements on Content and Format of Labeling for Human
@,T+W,O.*O01 t,)Q+& >T(O+O01 0S R@TVOo*,OW 9+T< =)n+TW*O01 O1 *PT ZonTLO1Qf GC aTVe >TQe o*
64,240.
88. Breslow, supra note 21, at 152U53; Fernandez Lynch, supra note 7, at 92U
93.
89. Regulations Requiring Manufacturers to Assess the Safety and
Effectiveness of New Drugs and Biological Products in Pediatric Patients, 63 Fed. Reg.
66,632, 66,632 (1998) (codified as amended in 21 C.F.R. §§ 312, 314 (1998))& #++81 0S #3ef
Physicians & Surgeons v. FDA, 226 F. Supp. 2d 204, 205 (D.C. Cir. 2002).
90. Regulations Requiring Manufacturers to Assess the Safety and
Effectiveness of New Drugs and Biological Products in Pediatric Patients, 63 Fed. Reg. at
66,632.
91. 226 F. Supp. 2d 204, 222 (D.C. Cir. 2002).
92. Id.
;PO+ W0),* V0T+ 10* .o++ N)VQ3T1* 01 *PT 3T,O*+ 0S *PT at#8+ ,TQ)Lo*0,j +WPT3Te
The Pediatric Rule may well be a better policy tool than the one enacted by
Congress; it might reflect the most thoughtful, reasoned, balanced solution to a
11
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Before the Pediatric Rule was finalized, the failures of the FDA to
improve the pediatric landscape prompted Congress to intervene with the
a00V o1V t,)Q #V3O1O+*,o*O01 Y0VT,1Oio*O01 #W* 0S KCCE hRat#Y#<gf
which provides drug manufacturers economic incentives for performing
pediatric drug studies.93 One of the most influential economic incentives was
contained in section 111 of the FDAMA, the BPCA, which was codified as
the pediatric exclusivity provision.94 The BPCA exclusivity provision was
targeted to improve pediatric labeling by dangling an economic incentive in
the form of a six-month extension to a drug ma1)SoW*),T,8+ .o*T1* 0,
exclusivity period in exchange for the manufacturer testing the drug in a
pediatric study.95 Although the provision did not require pediatric testing, it
was considered a success despite being riddled with limitations.96 These
limitations included: The voluntary participation by companies—the
provision only affected companies which had drugs on patent or were in an
exclusivity term at that particular point in time—and the provision was only
established to last for five years.97 Despite these limitations, the exclusivity
.,0(O+O01 PTL.TV O1WT1*O(OiT .TVOo*,OW ,T+To,WP LToVO1Q *0 *PT "@!#8+ ,T-
enactment in 2002.98 The BPCA became even more important to the FDA
oS*T, *PT @TVOo*,OW >)LT mo+ +*,)WMf o+ O* mo+ *PT at#8+ 01Lj ,T3oO1O1Q
means of directing a change in the pediatric landscape.99
C. Pediatric Involvement in Clinical Studies for Childhood Cancer
Prior to the 1990s, the regulations put into place to protect children
led to a small number of enrollees into pediatric oncology clinical trials.100
Since the early 2000s, this has not been the case as a large majority of
children fighting cancer in the United States enroll in Phase III clinical trials,
(TkO1Q .)nLOW PToL*P .,0nLT3e ;PT O++)T PT,T O+ 10* *PT >)LT8+ mO+V03e ^1VTTVf OS
that were the issue, this court would be a poor arbiter indeed. The issue is the
>)LT8+ +*o*)*0,j o)*P0,O*jf o1V O* O+ *PO+ *Po* *PT W0),* SO1V+ LoWMO1Qe
Id.
93. Breslow, supra note 21, at 153U55, 157 n.213; see also Food and Drug
Administration Modernization Act of 1997, Pub. L. No. 105-115, § 111, 111 Stat. 2296, 2305-
09 (codified as amended in scattered sections of 21 U.S.C.).
94. See 21 U.S.C. § 355c (2012); § 111, 111 Stat. at 2306U07; Breslow, supra
note 21, at 173U74.
95. 21 U.S.C. § 355c (b)U(c); Breslow, supra note 21, at 156 n.201, 173U74.
96. See Breslow, supra note 21, at 154.
97. See id. at 154U55, 156 n.201.
98. See Best Pharmaceuticals for Children Act of 2002, Pub. L. No. 107-109,
§ 3, 115 Stat. 1408, 1408 (codified as amended in scattered sections of 21 U.S.C.); Breslow,
supra note 21, at 162.
99. Cohen, supra note 16, at 661 (emphasis in original).
100. Oberman & Frader, supra note 40, at 301.
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which are experimental treatments.101 A majority of children with cancer
become an experimental subject compared to a small minority of adults,
signifying a lack of concrete medical options for children battling cancer.102
Until the 1960s, there was no effective treatment that children suffering from
this life-threatening disease[] could look towards for help.103 Around that
*O3Tf O* PoV nTW03T o..o,T1* *Po* O1 0,VT, *0 +o(T WPOLV,T18+ LO(T+f WLO1OWoL
studies were required, but at the same time, regulations to safeguard children
were being put in place.104
R^1 LT++ *Po1 PoLS 0S o WT1*),jf< WLO1OWol studies and pediatric cancer
research combined to make great strides in the pediatric oncology field.105
The success of these studies helped turn the tide in American thinking to
allowing children to partake in medical studies.106 Progress in treatment
devTL0.3T1* S0, _)3o1 ^33)10VTSOWOT1Wj 7O,)+ hR_^7<g o1V Wo1WT, Po(T
particularly led the way in transforming the perception of children partaking
in medical studies.107 But despite the medical progress, there have been
some societal conflicts regarding children partaking in clinical trials,
especially Phase I trials.108 Phase I clinical trials are used to determine,
R*0kOWO*jf 3T*on0LO+3f on+0,.*O01f TLO3O1o*O01f o1V 0*PT, .Po,3oW0L0QOWoL
oW*O01e<109 The purpose behind a Phase I study is not for therapeutic benefit;
all benefits are incidental, or indeed coincidental, because its essential use is
*0 RVT*T,3O1T *PT 3okO3)3 V0+T o* mPOWP *PT V,)Q Wo1 +oSTLj nT
*0LT,o*TVe<110
An issue present in treating children is the fact that introducing new
treatments for children requires pediatric subjects be put through clinical
trials—Phase I, II, and III—as rigorous as those for adults.111 R!POLV,T1
VOSST, .Pj+O0L0QOWoLLj S,03 oV)L*+f< +0 *PT Vo*o LTo,1TV *P,0)QP o1 oV)L* *,OoL
can be useless and even dangerous for pediatric use.112 In order to benefit
101. Id.
102. Id. at 302.
103. Id.
104. Id.
105. Oberman & Frader, supra note 40, at 302.
106. Id.
107. Id. at 304.
108. Id. at 304U05.
109. George J. Annas, Questing for Grails: Duplicity, Betrayal and Self-
Deception in Postmodern Medical Research, 12 J. CONTEMP. HEALTH L. & POL8Y 297, 310
(1996) (quoting PRESIDENT8S COMM8N FOR THE STUDY OF ETHICAL PROBLEMS IN MED. &
BIOMEDICAL & BEHAVIORAL RESEARCH, PROTECTING HUMAN SUBJECTS 64 (1981)). Phase II
studies follow Phase I studies and are focused on safety and biological effects. Oberman &
Frader, supra note 40, at 308.
110. Oberman & Frader, supra note 40, at 305.
111. Id.
112. Id.
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future patients and continue to make progress, these studies are necessary,
but even this future benefit cannot be the sole justification for subjecting
these children to clinical experimentation.113 But, children in Phase I studies
are extremely ill, and have not responded to standard treatment, so these
patients volunteer for these trials because the patient and/or their family
R1o*),oLLj (OTm ,T+To,WP o+ *PTO, nT+* WPo1WT qS0,p +),(O(oLe<114 This is called
therapeutic misconception.115 The desperation to find a cure drives a sick
patient to believe that Phase I clinical trials constitute a treatment more than
a non-therapeutic medical experimentation.116
Tension in conducting Phase I clinical trials challenges every party
attempting t0 .,0*TW* *PT WPOLV8+ nT+* O1*T,T+*e117 As a minor, a child is not
legally autonomous and cannot consent to their own healthcare, especially to
enroll themselves into clinical trials.118 ;PT WPOLV8+ Q)o,VOo1h+gf )+)oLLj
parents, must authorize enrollment into these trials.119 Another issue present
O1 o WPOLV8+ T1,0LL3T1* O1*0 o @Po+T ^ *,OoL O1(0L(T+ *PT .o,T1*8+ VTWO+O01 *0
enroll a terminally ill child into a clinical study.120 A parent may not have
the best interests of the child in mind when faced with such a decision.121
Parents of a terminally ill child may have an unrealistic hope that the child
mOLL O3.,0(T VT+.O*T *PT VO+To+T 0, R3oj W01+T1* *0 ,T+To,WP O1 o1 TSS0,* *0
0n*oO1 o +T1+T 0S W01*,0L 0(T,< *PT VTo*P 0S *PTO, WPOLVe122 With our interest
in safeg)o,VO1Q o WPOLV8+ nT+* O1*T,T+*f O* 3OQP* 1T(T, nT .0++OnLT *0 Po(T o
rational justification for Phase I research with children, but these studies
must always continue with the best interest of the child in mind.123
113. Id.
114. Id. at 306, 308UcCe RA1T +),(Tj 0S WLO1OWoL ,T+To,WPT,+ S0)1V *Po* q1O1T*j-
S0), .T,WT1*p oQ,TTV *Po* oV)L* .o*OT1*+ T1,0LL O1 @Po+T ^ +*)VOT+ :30+*Ly for the possible
3TVOWoL nT1TSO*e8< AnT,3o1 / a,oVT,f supra note 40, at 309 (quoting Eric Kodish et al.,
Ethical Issues in Phase 1 Oncology Research: A Comparison of Investigators and
Institutional Review Board Chairpersons, 10 J. CLINICALONCOLOGY 1810, 1812 (1992)).
115. Id. at 308.
116. Id.
117. See id.
118. Id. at 314.
119. Oberman & Frader, supra 10*T Hcf o* IKHe R;PT on+T1WT 0S o +)n+*O*)*TV
judgment model for parental decision-making suggests that we view the parent-child
relationship as unique and regard WPOLV,T1 o1V *PTO, .o,T1*+f O1 +03T +T1+Tf o+ o +O1QLT )1O*e<
Id. at 315.
120. See id. at 314U15.
121. See id. at 315.
122. Id. at 315.
123. Oberman & Frader, supra note 40, at 317.
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III. THE CARROT AND STICKAPPROACH: THE Ft#8S TANDEM SYSTEM
DESIGNED TO CHANGE THE LANDSCAPE OF PEDIATRICMEDICINE
Costs of clinical trials, especially those in pediatrics, continue to rise
and without legislation in place to act as an incentivizing device,
pharmaceutical companies would have little economic interest in pursuing
pediatric trials.124 Currently, many companies will typically pursue pediatric
use in a developing adult drug, which if it has shown promise in children, is
because of the carrot or [the] stick.125 The Pediatric Rule and FDAMA were
the original stick and carrot meant to ensure drugs would be tested in
children.126 But statutory issues leading to the suspension of the Pediatric
>)LT o1V LO3O*o*O01+ T3nTVVTV O1 *PT at#Y#8+ TkWL)+O(O*j .,0(O+O01 LTV *0
legislative changes in the early 2000s.127
The BPCA of 2002—reauthorized in 2007—provides drug
W03.o1OT+ mO*P Ro1 oVVO*O01oL +Ok 301*P+ 0S 3o,MT*O1Q TkWL)+O(O*j qS0, *PTO,p
.o*T1*TV V,)Q< O1 TkWPo1QT S0, W01V)W*O1Q o1 at#-requested pediatric
study.128 The reward-based arrangement provided an incentive for
pharmaceutical companies to test their drugs on pediatric populations, thus
the carrot of the modern day regulatory system for pediatric research.129
The PREA of 2003—also reauthorized in 2007—authorizes the FDA
with the ability to force testing of new drugs in a pediatric population by the
drug manufacturer.130 This law awarded the FDA with the power to require
pediatric testing of drugs already in the market stream, as well as drugs not
yet approved by the FDA.131 The BPCA was created to increase information
available about the use of drugs in children through economic incentives, and
124. Jerles, supra note 13, at 526U27.
125. Megan Scudellari, *he Ei$s 4ren’t 4PP ,ight: The Number of Children
Dying of Cancer Is Climbing, Yet New Medications to Treat Them Are Achingly Scarce,
NEWSWEEK, Aug. 7, 2015, at 44, 46.
126. Ross & Walsh, supra note 49, at 322.
127. See Breslow, supra note 21, at 162; Ross & Walsh, supra note 49, at 322U
23.
128. Scudellari, supra 10*T KJGf o* HFe Ra0, o V,)Q *Po* To,1+ 4K nOLLO01 .T,
jTo,f *Po*8+ o1 Tk*,o 4Gcc 3OLLO01 qo W03.o1j W0)LV To,1p S0, o .TVOo*,OW +*)Vj *Po* mOLL W0+* o
S,oW*O01 0S *Po*e< Id. It provides an economic incentive for pharmaceutical companies. See
Best Pharmaceuticals for Children Act of 2002, Pub. L. No. 107-109, § 10, 115 Stat. 1408,
1415 (codified as amended on scattered sections of 21 U.S.C.); Scudellari, supra note 125, at
46.
129. Fernandez Lynch, supra note 7, at 94.
130. Pediatric Research Equity Act of 2003, Pub. L. No. 108-155, §
505B(a)(2), 117 Stat. 1936, 1936 (codified as amended in scattered sections of 21 U.S.C.);
Scudellari, supra note 125, at 46.
131. Fernandez Lynch, supra note 7, at 95; Jerles, supra note 13, at 521.
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*PT @>b#8+ 3o1Vo*T S0, .TVOo*,OW *T+*O1Q +)..0,*+ *Po* (O+O01f .,0(OVO1Q R*PT
stick *0 *PT "@!#8+ carrote<132
A. The Incentive-3ase$ @2arrot/Q *he 3est -har8aceuticals for
Children Act
The expiration of the FDAMA in 2001 led to the enactment of the
BPCA in 2002.133 A lack of prescriptions being tested and approved for use
in children, as well as dosing adult medication to children based solely on
weight, led Congress to intervene.134 Additionally, because drugs were
designed with adults in mind, the absence of age-appropriate formulations
and devices for use were causing difficulties among pediatric patients.135
Congress enacted the BPCA upon a finding that the exclusivity provision of
the FDAMA had positively impacted the pediatric population unlike any
legislation prior.136
BPCA of 2002 continued the goal of the FDAMA but made some
alterations, such as eliminating the Pediatric List which did not meet its
intended goal of effectively prioritizing the certain drugs that should have
been tested in children.137 Although pediatric testing is not required and
remains voluntary, the 2002 BPCA set a two-level system in place where the
FDA researches current drugs to determine if it may produce a benefit to
pediatric populations.138 If the FDA were to find a drug that shows potential
to produce benefits to pediatric populations, the FDA will send a written
request to the patent holder to perform a pediatric clinical study with its
drug.139 If the patent holding company decides to perform the requested
pediatric clinical trials centered around its own drug, it would earn an
additional six-month term of market exclusivity.140 This additional six
months of market exclusivity acts as an incentive for these companies to
perform pediatric studies.141 But due to the voluntary nature of the statute, a
patent holder can choose not to perform the requested pediatric clinical
132. Fernandez Lynch, supra note 7, at 95.
133. § 1, 115 Stat. at 1408; Jerles, supra note 13, at 517.
134. Jerles, supra note 13, at 516.
135. Id. at 517, 527.
136. Id. o* GKEe R;PT "@!# O1W,To+T+ *PT Wo.oWO*j 0S *PT at#f T1onLO1Q O* *0
handle its new role as the initiator and arbitrator of pediatric studies—something that the
0,OQO1oL nOLL PoV SoOLTV *0 V0e< ",T+L0mf supra note 21, at 178.
137. Jerles, supra note 13, at 518.
138. Breslow, supra note 21, at 134.
139. Jerles, supra note 13, at 518.
140. Breslow, supra note 21, at 134; Jerles, supra note 13, at 518.
141. Jerles, supra note 13, at 518.
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study.142 If the patent holder opts not to perform the requested study, the
statute allows the FDA to contract out of the drug testing, with entities that
have pediatric clinical trial expertise, such as universities and hospitals.143
Additionally, a significant addition to the BPCA of 2002 was the
creation of a program to test off-patent drugs, which the FDAMA lacked
prior.144 This reform was called the Program for Pediatric Studies of Drugs
ZoWMO1Q bkWL)+O(O*j hR@,0Q,o3<ge145 This Program called for the FDA and
NIH to work together to develop a list of off-patent or off-exclusivity drugs
that show potential to produce a benefit to the pediatric populations.146
Under the BPCA, the FDA may issue written requests to the application
holders of a drug that is deemed to require more research.147 If the
application holders do not respond within thirty days of the request, or
choose not to conduct the requested pediatric trials with the drug, the FDA
can then publish requests for proposals from entities with pediatric clinical
trial expertise.148
The BPCA of 2002 also requires that any pediatric report, conducted
pursuant to a written request for a clinical trial, must be published in the
Federal Register within 180 days after it has been submitted to the FDA.149
Additionally, in response to lack of pediatric labeling, the BPCA awards the
FDA the power to deem a drug mislabeled.150 When the drug manufacturer
,TS)+T+ *0 oWWT.* *PT at#8+ VTWO+O01 S0, o LonTLO1Q WPo1QTf *PT "@!# oLL0m+
the FDA to bring an enforcement action under the Federal Food, Drug, and
Cosmetic Act.151 Lastly, due to the unease from the pediatric oncologist
community, the BPCA attempts to increase research performed in their field
which despite the exclusivity provision, was markedly absent.152 This
attempt culminated in the creation of a Pediatric Subcommittee of the
Oncologic Drugs Advisory Committee to evaluate cancer drugs and
prioritize which would be of the most use for children.153 Though the
142. Breslow, supra note 21, at 134.
143. Id.; Jerles, supra note 13, at 518.
144. Breslow, supra note 21, at 174U76.
145. Id. at 174; see also 42 U.S.C. § 284 (2012).
146. 42 U.S.C. § 284(a) (2012); Breslow, supra note 21, at 174.
147. 42 U.S.C. § 284(c) (2012); Breslow, supra note 21, at 174.
148. 42 U.S.C. § 284(c)(3) (2012). Once a drug application holder has
declined to conduct a test or misses the thirty-day deadline, it is not eligible to respond to a
written request for a contract from the FDA. Id. § 284(c)(4).
149. Best Pharmaceuticals for Children Act of 2002, Pub. L. No. 107-109, § 9,
115 Stat. 1408, 1415 (codified as amended in scattered sections of 21 U.S.C.); Breslow, supra
note 21, at 175.
150. § 3, 115 Stat. at 1408; Breslow, supra note 21, at 175.
151. 42 U.S.C. § 284(c)(10)U(11) (2012); Breslow, supra note 21, at 175.
152. Breslow, supra note 21, at 178.
153. Id.
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participation under BPCA is voluntary and in the control of the
pharmaceutical companies, the BPCA attempts to compensate for the
voluntary nature by including programs, such as the Pediatric Studies
Program or the Pediatric Subcommittee of the Oncologic Drugs Advisory
Committee, which will help facilitate and begin research drugs that are not
researched by the pharmaceutical companies.154
B. *he -e$iatric ,esearch O51itJ 4ctQ *he @+ticR/ to the 3-24’s
@2arrot/
The purpose of the BPCA of 2002 was to increase the amount of
research on drugs that children were using due to the lack of labeling and
dosages.155 Despite the success of the earlier exclusivity provision, Congress
believed that the voluntary testing established under the BPCA was not
adequate and thought the FDA needed the requisite authority to mandate
pediatric testing.156 Additionally, the Pediatric Rule had just been
invalidated by a United States District Court in 2002, which held that the
>)LT TkWTTVTV *PT at#8+ +*o*)*0,j o)*P0,O*je157 Due to the importance of
.,0.T, LonTLO1Q 0S .TVOo*,OW V,)Q+ o1V !01Q,T++8 nTLOTS *Po* *PT at# 1TTVTV
the authority to mandate pediatric testing, Congress enacted the Pediatric
Research Equity Act of 2003.158
The PREA of 2003 gave the FDA the authority to require pediatric
testing of drugs already present in the market as well as mandating pediatric
testing and labeling on all drugs that have not been approved by the FDA.159
This enactment was meant to be non-voluntary support for the voluntary
exclusivity provision within its sister statute, the BPCA of 2002.160 The
PREA of 2003 mandates that pharmaceutical companies must, when
submitting a new drug application, submit sufficient information regarding
the clinical indication of the drug in relevant pediatric subpopulations, even
if the drug was not intended for pediatric use.161 Additionally, this statute
154. Id. at 181U82.
155. See § 3, 115 Stat. at 1408U09; Breslow, supra note 21, at 146; Jerles,
supra note 13, at 520U21.
156. Jerles, supra note 13, at 520.
157. #++81 0S #3ef @Pj+OWOo1+ / =),QT01+ (e at#f JJF ae =)..e JV JcHf JJJ
(D.C. Cir. 2002).
158. Pediatric Research Equity Act of 2003, Pub. L. No. 108-155, § 1, 117
Stat. 1936, 1936 (codified as amended in scattered sections of 21 U.S.C.); Jerles, supra note
13, at 521.
159. § 2, 117 Stat. at 1936U39; Fernandez Lynch, supra note 7, at 95; Jerles,
supra note 13, at 521.
160. Fernandez Lynch, supra note 7, at 94U95.
161. § 2, 117 Stat. at 1936; Fernandez Lynch, supra note 7, at 95U96.
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mandates drug manufacturers to submit data supportO1Q )+T O1 R.TVOo*,OW
+)n.0.)Lo*O01+ O1 mPOWP *PT V,)Q O+ S0)1V *0 nT +oST o1V TSSTW*O(Te<162
Furthermore, the PREA allows the FDA to require the drug
manufacturers to produce sufficient data supporting use in pediatric
subpopulations for drugs already approved and actively on the open
market.163 Because these drugs are already approved, they do not fall under
the same classification as a new drug application.164 Despite receiving
authority to require data for existing drugs, the FDA could only mandate the
drug manufacturer to conduct pediatric testing after requesting the
manufacturer to voluntarily conduct the research.165 The FDA has the
authority to require pediatric data for existing drugs if the drug is used
substantially among pediatric populations for the designated use on the label,
or if there is the possibility the drug could provide an upgraded therapeutic
benefit over the drugs being used for pediatric patients at that time.166
Additionally, the FDA must show that the absence of proper labeling could
create substantial risks for the pediatric population.167 Similar to the
procedure for new drugs yet to be approved, if the drug manufacturer agreed
to conduct the research voluntarily, the manufacturer was awarded the
additional six months of market or patent exclusivity pursuant to BPCA of
2002.168 If the manufacturer refused to conduct the pediatric research
regarding the drug, the FDA would then refer the study to the Foundation for
the National Institute of Health and proceed to contract the study out to an
entity with pediatric clinical trial expertise.169
C. Results Following BPCA 2002 and PREA 2003: The Reenactment of
the Carrot and Stick Approach
The complexity of conducting childhood studies places barriers
around the field, discouraging drug manufacturers from aiming their
products at a pediatric audience.170 Economically speaking, the manufacturer
sees no reason to change the current system, which allows pediatricians to
prescribe drugs off-label.171 In economic terms, a drug manufacturer can
save money without expending additional effort by continuing to target adult
162. Fernandez Lynch, supra note 7, at 96 (citing § 2, 117 Stat. at 1936).
163. Id. at 95U96; see also § 2, 117 Stat. at 1936U37.
164. Fernandez Lynch, supra note 7, at 95U96, 96 n.102.
165. Jerles, supra note 13, at 522.
166. Fernandez Lynch, supra note 7, at 96.
167. § 2, 117 Stat. at 1938; Fernandez Lynch, supra note 7, at 96U97.
168. Jerles, supra note 13, at 518, 522.
169. Id. at 518.
170. Id. at 526.
171. Id.
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use, choosing not to conduct voluntary pediatric clinical studies, and
allowing the doctors to keep prescribing drugs off-label.172 Additionally, due
to some problems in BPCA 2002 and PREA 2003, pharmaceutical
companies did not have very much difficulty avoiding these regulations.173
While these laws pursued improvement and increased availability of drugs to
children, both had some negative results in the areas that were designated for
upgrades.174
Companies would manipulate BPCA 2002 and PREA 2003 to their
advantage, using several loopholes—riddling these laws.175 Clinical trial
testing takes a very long time to complete; therefore, results do not occur
quickly.176 Both of these laws were enacted for such a short time, thus drug
manufacturers would take advantage of the length needed for a clinical trial
and delay testing with the hopes of the legislation expiring.177 Furthermore,
shortly before the expiration of their patent—sometimes days—a drug
manufacturer could submit data from pediatric testing.178 In addition to
filing a last second application, the FDA was required to review the results
within ninety days, giving drug companies a de facto three month exclusivity
period, even if inadequate testing was performed.179 Even if the FDA rejects
an inadequate study, the drug company is awarded an additional three
months of exclusivity for their drug, making a profit at the expense of
pediatric studies.180
Pediatric care requires a completely different mindset than adult
care, ranging from the devices used for application of the drug to the way
children metabolize drugs.181 Although it is looked at as the cheap
alternative by pediatricians, it is practical to prescribe off-label drugs to
children, but for many drugs to work properly, they must be re-sized to suit
application in children and not adults.182 Even though these laws were
perforated with problems, since enactment, they have helped change the
172. Id.
173. Jerles, supra note 13, at 526U27.
174. Id. at 527.
175. Id.
176. Id. at 526.
177. Id. Drug manufacturers who had begun clinical trials also took advantage
of the length needed to complete a trial. Jerles, supra note 13, at 526. Clinical trials likely
require longer than four years to complete, but the laws only mandated testing for four years.
Id.
178. Id. at 527.
179. Id.
180. Id.
181. Jerles, supra note 13, at 516U17, 527.
182. Id. at 527.
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perception of children in the medical field in a much more positive light.183
Despite many pharmaceutical companies taking advantage of the many
loopholes within these laws, the motivation of patent extensions to seek
approval for pediatric use was a step in the right direction.184
Although there were steps taken in the right direction, as well as an
increased availability of clinical studies for children, there was very little
advancement regarding the development of drugs specifically for use in
children.185 Drug companies test already developed drugs on pediatric
subjects, typically recruiting pediatric patients for general tests conducted on
everyone afflicted by a certain condition and not just on children.186 By
testing the effects of drugs already approved for adults, pharmaceutical
companies still receive the benefit of an additional six months of market
exclusivity—QO(O1Q *PT3 RLO**LT O1WT1*O(T *0 VT(TL0. q1Tmp V,)Q+ +.TWOSOWoLLj
S0,< )+T O1 .TVOo*,OW .0.)Lo*O01+e187 Although the legislation was made in an
effort to update labeling of existing drugs and to develop an increased
1)3nT, 0S 1Tm V,)Q+ S0, .TVOo*,OW .o*OT1*+f *PT+T Lom+ RO1WT1*O(OiTqp qV,)Qp
manufacturers to test drugs already approved for adults, rather than develop
1Tm V,)Q+ S0, WPOLV,T1f< nTWo)+T O* O+ 3)WP LT++ .,0SO*onLTe188 This has led to
a large increase in therapies available to children, but with little increase in
drugs developed specifically for use in children.189 Additionally, when
testing drugs on children, drug manufacturers have typically used more cost-
cutting methods.190 When conducting a clinical trial on adult drugs, a
W03.o1j8+ SO,+* +*T. O+ )+)oLLj *0 +*)Vj *PT on+0,.*O01 0S o .o,*OW)Lo, V,)Q
and how it is metabolized before effectiveness is tested.191 But in order to
cut costs of pediatric clinical trials, these drug manufacturers combine both
testing for absorption and effectiveness, leading to trials that drag on causing
pediatric patients to deny enrollment.192
Another issue present within these laws deals with the lack of
negative data disclosure from clinical trials.193 Different journals of
medicine created either voluntary databases to input results, or started to
require trials registered with the public clinical trial registry to be published
183. Id. at 527U28.
184. Id. at 528.
185. Id. at 531.
186. Jerles, supra note 13, at 530U31.
187. Id. at 531.
188. Id. at 532.
189. Id.
190. Id. at 542.
191. Jerles, supra note 13, at 542U43.
192. Id. at 543.
193. Id. at 539.
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in that journal.194 ;PT aoO, #WWT++ *0 !LO1OWoL ;,OoL+ #W* hRa#!; #W*<g mo+
introduced in 2005 for the FDA to expand the existing database to make
clinical results more readily available to the public.195 Under the FACT Act,
results of both publicly and privately funded clinical trials would be
published, despite the results.196 In 2006, a modified version of the FACT
Act was introduced, the Enhancing Drug Safety and Innovation Act.197 This
limited what was published, and no longer required devices or procedures to
be published—only detailed information regarding the drug and its approval
status.198 Neither of these bills passed, and were deferred to the Senate
Committee on Health, Education, Labor, and Pensions.199
1. Revival: ;PT >TT1oW*3T1* 0S *PT R!o,,0* o1V =*OWM<
Despite having several problems, both acts were reauthorized upon
their expiration in 2007.200 Both were reenacted for another five years as
part of larger legislation, the Food and Drug Administration Amendments
#W* 0S JccE hRat###<ge201 The FDAAA helped close some of the existing
loopholes and fix other issues which were taken advantage of by
pharmaceutical companies.202 Also, an important addition to this act helped
pave the way for age-appropriate devices for application of adult drugs in
children, with the Medical Device Safety and Improvement Act of 2007.203
This Act curtails off of the incentive driven attitude of the BPCA, and
provides incentives in exchange for the creation of products that children can
use for treatments.204 Along with providing incentives for creating products
for children, the Act requires that companies pursuing approval for a device
have to include description[s] of . . . pediatric subpopulations which are
afflicted by the issue the device is aimed to fix.205 Further, the Act inspired
pediatric device research because within 180 days of enactment, the FDA
194. Id.
195. Id. at 539U40; see also Fair Access to Clinical Trials Act of 2005, S. 470,
109th Cong. § 2(1)U(4)(2005).
196. Jerles, supra note 13, at 540.
197. Id. at 541; see also Enhancing Drug Safety and Innovation Act of 2006, S.
3807, 109th Cong. § 1 (2006).
198. Jerles, supra note 13, at 541.
199. Id. at 542.
200. Id. at 516.
201. Id.; see also Food and Drug Administration Amendments Act of 2007,
Pub. L. No. 110-85, § 1, 121 Stat. 823, 823 (codified as amended in scattered sections of 21
U.S.C.).
202. See Jerles, supra note 13, at 544.
203. See § 301-07, 121 Stat. at 859U66; Jerles, supra note 13, at 516.
204. See § 301-07, 121 Stat. at 859U66; Jerles, supra note 13, at 516.
205. § 302, 121 Stat. at 859.
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was required to publish a pediatric device research agenda which was to be
followed in the development stage.206
a. The BPCA of 2007
The FDAAA of 2007 enacted the BPCA of 2007, a reenactment of
the BPCA 2002, with some adjustments.207 One major issue BPCA of 2007
was targeted to fix was the situation where pharmaceutical companies could
submit pediatric test results, immediately before the patent expired, to
attempt to receive patent exclusivity for a maximum of nine months or
minimum of three months.208 BPCA 2007, with the intentions of improving
the pediatric landscape, aimed to close this loophole by not only removing
*PT .T,O0V 0S TkWL)+O(O*j V),O1Q *PT at#8+ ,T(OTmf n)* oL+0 V0)nLO1Q *PT *O3T
of review from ninety days to 180 days, awarding the FDA much more time
to analyze the results provided.209 This effectively removed the ability of
pharmaceutical companies to provide inadequate pediatric testing yet reap
the benefits of up to nine extra months of exclusivity, three for those
companies who provided extremely inadequate pediatric testing.210
b. The PREA of 2007
Like the BPCA of 2007, the FDAAA of 2007 enacted the PREA of
2007, which reenacted the PREA of 2003.211 The PREA of 2007 was
designed to make some changes to the prior law.212 The law removed the
requirement that the FDA request a pharmaceutical company to conduct
pediatric tests voluntarily before having the authority to mandate testing.213
Without that nuance, the FDA was granted the authority to mandate pediatric
testing by pharmaceutical companies, thus avoiding the unnecessary steps
206. § 304, 121 Stat. at 863.
207. Best Pharmaceuticals for Children Act of 2007, Pub. L. No. 110-85, §
501-02, 121 Stat. 876, 876 (codified as amended in scattered sections of 21 U.S.C.).
208. See § 505A, 121 Stat. at 877; Best Pharmaceuticals for Children Act of
2002, Pub. L. No. 107-109, § 3, 115 Stat. 1408, 1408U10 (codified as amended in scattered
sections of 21 U.S.C.). Under BPCA 2002, pharmaceutical companies could send inadequate
pediatric data to the FDA and reap the benefits of a de-facto exclusivity period while the FDA
reviewed the findings, thus taking advantage of the law in place. See § 3, 115 Stat. at 1408U
10.
209. Jerles, supra note 13, at 519; see also § 505, 121 Stat. at 879.
210. Jerles, supra note 13, at 519U20.
211. Id. at 519, 522; see also Pediatric Research Equity Act of 2007, Pub. L.
No. 110-85, § 402, 121 Stat. 866, 866 (codified as amended in scattered sections of 21
U.S.C.).
212. Jerles, supra note 13, at 522; see also § 402, 121 Stat. at 869.
213. Jerles, supra note 13, at 522; see also § 402, 121 Stat. at 869.
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which delayed progress.214 Two major requirements added to the PREA of
2007 helped to improve the landscape of pediatric medicine and increased
*PT at#8+ .0mT, *0 3o1Vo*T *T+*O1Qe215 First, the PREA of 2007 required
pharmaceutical companies to provide more detailed data in support of a
waiver requesting permission for pediatric testing of their drug.216 Second,
the law requires the FDA to assess the effectiveness of the law through
conducting studies with the Institute of Medicine and the Government
Accountability Office years after the law, which will help the FDA formulate
a plan of attack for the future.217
IV. RACE: THE RESEARCH TOACCELERATE CURES AND EQUITY FOR
CHILDRENACT
As previously mentioned, pediatric cancer is the number one killer
among children.218 Very little is known about childhood cancers, as the
types of cancers and biology of childhood cancers are much different from
adult cancers.219 PREA and BPCA were enacted first in 2003 and then
reenacted in 2007 to increase pediatric research to develop drugs specifically
for use in children.220 ;PT R"@!# PoqVp m0,MTV ,To+01onLj mTLL S0, V,)Q+
mO*P qop Lo,QT 3o,MT*< S0, )+Tf n)* +*OLL ,T3oO1+ (0L)1*o,jf o1V V0T+ 10*
support drugs for smaller markets, such as cancer.221 Almost every single
instance under PREA, cancer drugs that have already been developed for
adults receive waivers eliminating the requirement to conduct pediatric
cancer studies.222 Children with cancer have been victims of pharmaceutical
companies abusing loopholes within the law.223 bkT3.*O01+ O1 @>b# RPo(T
nTT1 n,0oVLj o..LOTV *0 Wo1WT,e<224 Legislation originally introduced in 2016
and reintroduced February of 2017 has aimed to end this abuse.225 The
214. See Jerles, supra note 13, at 522.
215. Id.; see also § 402, 121 Stat. at 866.
216. Jerles, supra note 13, at 522; see also § 402, 121 Stat. at 868U69.
217. Jerles, supra note 13, at 522; see also § 402, 121 Stat. at 874U75.
218. Childhood Cancers, supra note 2.
219. See Childhood Cancers Research, NAT8L CANCER INST.,
http://www.cancer.gov/research/areas/childhood (last updated Sept. 1, 2017).
220. Jerles, supra note 13, at 528, 531U32; see also Best Pharmaceuticals for
Children Act of 2007, Pub. L. No. 110-85, § 502, 121 Stat. 876, 876 (codified as amended in
21 U.S.C.); § 402, 121 Stat. at 866; Fernandez Lynch, supra note 7, at 94U95.
221. Adamson et al., supra note 7, at 737.
222. Id.
223. Cures for All: US Lawmakers Should Give Drug Firms the Confidence to
Test Cancer Therapies in Children, supra note 18, at 466.
224. Id.
225. Id.; see also Research to Accelerate Cures and Equity for Children Act,
H.R. 1231, 115th Cong. § 2 (as introduced in House, Feb. 27, 2017); Research to Accelerate
24
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>T+To,WP *0 #WWTLT,o*T !),T+ o1V b-)O*j S0, !POLV,T1 #W* hR>#!b<g mo+
in*,0V)WTV *0 O3.,0(T WPOLV,T18+ oWWT++ *0 1Tmf .,03O+O1Q V,)Q+—thus
improving current cancer treatments considerably.226 R>#!b ).Vo*T+ *PT
JccI @>b# Lomf< mPOWP ,T-)O,T+ .TVOo*,OW *T+*O1Q V),O1Q VT(TL0.3T1* 0S
adult drugs.227 RACE updates PREA to more adequately reflect current
advances in oncology drug development by removing the exemptions, which
have halted the development of new pediatric cancer drugs.228
A. The Issues RACE Aims to Resolve
BPCA and PREA have generated major safety and labeling data for
severoL WPOLV,T18+ VO+To+T+e229 Despite producing hundreds of successful
Wo+T+ mPOWP .,0(OVT O1W,TVOnLT Vo*o 01 V,)Q )+T O1 WPOLV,T1f Rq@>b#p Po+
1T(T, nTT1 o..LOTV *0 o .TVOo*,OW Wo1WT, V,)Qe<230 The current PREA law
was written with some significant loopholes, which are in the form of broad
exemptions in pediatric cancer drug development, thus awarding drug
manufacturers a waiver from completing pediatric studies.231 PREA requires
pharmaceutical companies to conduct pediatric testing while developing a
drug for use in adults.232 These loopholes have prevented children with
cancer from accessing the newest and most promising drugs.233 As drug
development in oncology has advanced over the past fifteen years, these
issues have arose out of the language of PREA not growing simultaneous
with those advances.234 Currently, instead of targeting specific types of
cancers, drugs are developed by targeting genes and proteins that are shared
in children and adults.235 This method is called molecular targeting.236
Cures and Equity for Children Act, S. 456, 115th Cong. § 2 (as introduced in Senate, Feb. 27,
2017).
226. KIDS V CANCER, supra note 5; see also H.R. 1231 § 2; S. 456 § 2.
227. McCaul et al., supra note 33.
228. See id.; KIDS V CANCER, supra note 5.
229. A RACE to the Finish!, supra note 25.
230. McCaul et al., supra note 33.
231. Id.
232. A RACE to the Finish!, supra note 25.
233. Cures for All: US Lawmakers Should Give Drug Firms the Confidence to
Test Cancer Therapies in Children, supra note 18, at 466.
234. See Allen, supra note 26; McCaul et al., supra note 33.
235. Allen, supra note 26.
236. Id.
The current approach to licensing drugs is based on their pathological indication
rather than their mechanism of action, even though the drug target for a common
adult cancer, such as ALK in non-small-cell lung cancer, can be present and
therapeutically relevant in a pathologically distinct childhood cancer, such as
neuroblastoma.
Adamson et al., supra note 7, at 737.
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PREA has not benefi**TV WPOLV,T1 nTWo)+T WPOLV,T18+ Wo1WT, O1O*Oo*T+
in different parts of the body than adult cancers.237 Due to the current PREA
law, drug manufacturers receive waivers for drugs that target adult cancers
because the common adult cancers these drugs are being developed for, do
not occur in children.238 However, some pediatric cancers share the same
molecular targets as adult cancers, despite originating in different organs.239
Due to the language of the legislation, PREA only applies when the diseases
are the same in both the child and the adult, meaning the cancer has to
originate in the same part of the body.240 This results in the first exemption
*Po* Po+ W01+*,oO1TV @>b#8+ O3.oW* 01 WPOLV,T1 mO*P Wo1WT,e241 Under
PREA, treatments developed for conditions in adults that do not effect
children are exempt from the requirements of pediatric testing.242 Thus,
pediatric studies during drug development can only be required where the
drug is being studied for the same disease or indication in both adults and
children.243 Because children do not develop many of the identical adult
cancers, pediatric studies are not performed.244
#10*PT, TkT3.*O01 *0 @>b#8+ ,T-)O,TV .TVOo*,OW *T+*O1Q o..LOT+
mPT1 *PT V,)Q RPoq+p ,TWTO(TV qo1p orphan VT+OQ1o*O01f< QO(T1 mPT1 o V,)Q
is being developed for a rare disease.245 A drug receives an orphan
designation when it affects 200,000 people or fewer in the United States.246
t)T *0 +WOT1*OSOW oV(o1WT+f *PT RonOLO*j *0 VTSO1T *PT 30LTW)Lo, no+O+ 0S o1
O1VO(OV)oL8+ Wo1WT, 3To1+ *Po* VOoQ10+T+ Po(T necome increasingly
subdivided, and the majority of approved cancer drugs now carry this orphan
VT+OQ1o*O01e<247 Recently, with this improved ability, has come a drastic
increase in the number of orphan designations.248 With no changes in the last
237. KIDS V CANCER, supra note 5.
238. Cures for All: US Lawmakers Should Give Drug Firms the Confidence to
Test Cancer Therapies in Children, supra note 18, at 466.
239. KIDS V CANCER, supra note 5. As an example, children with
neuroblastoma have been successfully treated by an ALK inhibitor that treats adults with lung
cancer. Id.
240. See Allen, supra note 26; McCaul et al., supra note 33.
241. A RACE to the Finish!, supra note 25.
242. Id.; see also Cures for All: US Lawmakers Should Give Drug Firms the
Confidence to Test Cancer Therapies in Children, supra note 18, at 466.
243. A RACE to the Finish!, supra note 25.
244. See id.
245. McCaul et al., supra note 33; see also Cures for All: US Lawmakers
Should Give Drug Firms the Confidence to Test Cancer Therapies in Children, supra note 18,
at 466.
246. Cures for All: US Lawmakers Should Give Drug Firms the Confidence to
Test Cancer Therapies in Children, supra note 18, at 466.
247. Id.
248. See id.
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fifteen years, the law has not been able to keep pace with medicine, thus
leaving children with a lack of updated treatment options.249
B. RACE to the Finish: The Impact of this Proposed Legislation
RACE is designed to fix the problems that riddle PREA and further
increase the opportunities for pediatric studies involving children with
cancer.250 RACE gives the FDA the necessary authority to require pediatric
investigation when drugs are being developed using molecular targeting and
the target identified in the adult cancer is substantively relevant to a form of
pediatric cancer.251 PREA requirements would apply to any therapy with a
molecular target that is relevant in both adult and childhood cancers; it does
not matter what part of the body the cancer existed or if it is the same type of
disease.252 This will help provide accurate labeling on drugs for pediatric
)+Tf RoLL0mqO1Qp V0W*0,+ *0 qT+*onLO+P W0,,TW*p V0+oQTq+pf +oST*jf o1V TSSOWoWj
O1 WPOLV,T1e<253 As new treatments emerge and proper dosages are studied,
doctors will no longer have to prescribe children off-label adult drugs and
can eventually prescribe drugs developed specifically for use in children.254
#VVO*O01oLLjf >#!b mOLL T1V @>b#8+ .TVOo*,OW +*)Vj TkT3.*O01 0S
orphan designated drug development.255 RACE requires pediatric
investigation during development of adult orphan drugs—no matter how
many people are afflicted by the disease and no matter where the cancer
originates in the body.256 Lastly, RACE includes an incentive to companies
that submit pediatric study plans To,Ljf mPOWP O1WL)VT+ To,LOT, at#8+ O1.)*
on those plans.257 The bill even attends to the most serious and life-
threatening diseases in children, as it directs the FDA to work with
pharmaceutical companies to speed up development of drugs in these
situations.258 Currently, treatment is limited for children suffering from some
249. Allen, supra note 26.
250. See A RACE to the Finish!, supra note 25.
251. McCaul et al., supra note 33.
252. See Cures for All: US Lawmakers Should Give Drug Firms the
Confidence to Test Cancer Therapies in Children, supra note 18, at 466. Studies have already
saved lives where the links between adult and pediatric molecular targets led to treatment.
McCaul et al., supra note 33. Some forms of pediatric neuroblastoma contain the same ALK
gene that appears in adult lung cancers. Id. ALK inhibiting treatment that was developed for
adult lung cancer has proven effective in certain neuroblastoma cases. Id.
253. McCaul et al., supra note 33.
254. Id.; Allen, supra note 26.
255. Cures for All: US Lawmakers Should Give Drug Firms the Confidence to
Test Cancer Therapies in Children, supra note 18, at 466.
256. McCaul et al., supra note 33.
257. KIDS V CANCER, supra note 5.
258. H.R. 1231 § 2(b)(1)(i)(I)U(II); S. 456 § 2(b)(1)(I)U(II).
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0S *PT 30+* WPoLLT1QO1Q S0,3+ 0S Wo1WT,f n)* Rq*pPT >#!b S0, !POLV,T1 #W*
could be the game-changer that finally offers children and their families the
best standard of care possinLTe<259
V. CONCLUSION
!POLV,T18+ O1(0L(T3T1* O1 3TVOWO1T Po+ oLmoj+ nTT1 o W01)1V,)3 0S
sorts.260 History has revealed that children have been on a proverbial
rollercoaster when it comes to their involvement in medicinal practices.261
At first, children lacked rights and were even considered as chattel—
belonging to their parents.262 Once the public was aware of the abuse
children were subjected to through clinical trials and studies, progress was
slowly made.263 As time passed, in the eyes of the public and the
government, children became a vulnerable class as they could not protect
themselves due to their lack of rights.264 Due to public outcry, the
government felt the need to safeguard children from the types of abuses they
had endured in the past.265
As medicine progressed over the course of the late twentieth century,
regulations were placed to further protect children from clinical trials and
studies.266 Though the intentions were sincere, these regulations slowed
down and even halted the development of new pediatric drugs and
treatments.267 While drugs had been developed for well-known and common
diseases, childhood cancer patients were often overlooked.268 Despite
general medical advances, the regulations in place provided little reason for
pharmaceutical companies to develop drugs for pediatric use, especially for
childhood cancer.269
259. McCaul et al., supra note 33.
260. See Breslow, supra note 21, at 135U136; Ross & Walsh, supra note 49, at
320.
261. See Breslow, supra note 21, at 135U136; Ross & Walsh, supra note 49, at
320.
262. Breslow, supra note 21, at 136.
263. See Fernandez Lynch, supra note 7, at 98; Ross & Walsh, supra note 49,
at 320.
264. See Fernandez Lynch, supra note 7, at 98; Oberman & Frader, supra note
40, at 301.
265. See Breslow, supra note 21, at 138U39; Oberman & Frader, supra note 40,
at 301.
266. See Breslow, supra note 21, at 138U39; Oberman & Frader, supra note 40,
at 301.
267. See Fernandez Lynch, supra note 7, at 85U86; Oberman & Frader, supra
note 40, at 301.
268. See Lynch, supra note 7, at 86.
269. Id.
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In the late 1990s, with momentum carrying into the 2000s, Congress
tried to take a stand to improve the availability of drugs for children.270
Programs were enacted to provide incentives for pharmaceutical companies
to test drugs in children to provide adequate labeling and other programs
were enacted to require testing in pediatric populations to hopefully result in
new treatments.271 As with many laws, these had to be reenacted upon
expiration to continue the progress but also to patch some holes within the
writing of the laws.272
Despite having overall success in many pediatric fields, these laws
did little to positively impact childhood cancer and the children suffering
from it.273 The laws in place were focused mainly on adult drugs, with little
development in drugs specifically for use in children, which incentivized
companies to test on adult drugs already on the market rather than formulate
drugs specifically for children.274 Loopholes in the most current laws
providing waivers to required pediatric testing have allowed companies to
avoid testing in childhood cancer all together, leaving children without
treatment designed for their specific illness.275
A new bill has been introduced to Congress that would end the
waiver exemptions.276 RACE updates the existing law to properly correlate
with the medical progress made over the last fifteen years.277 R>#!b e e e
Wo*WPT+ e e e *PT Lom q).p mO*P *PT +WOT1WT e e e e<278 Rick Allen, who represents
the Twelfth Congressional District of Georgia, has called this commonsense
legislation, and if there was ever a time to classify it as such, the time is
now.279 As of July 2017, the House of Representatives included RACE in a
larger piece of legislation, the FDA Reauthorization Act of 2017, which
unanimously passed in the House.280 The passage of this legislation is
W,)WOoL O1 *PT SOQP* *0 +o(T WPOLV,T18+ LO(T+f o+ Tk.,T++TV nj 9e=e =T1o*0,
Chris Van Hollen when he professed:
270. Id. at 93.
271. See Breslow, supra note 21, at 133U34.
272. See Jerles, supra note 13, at 519, 528.
273. Adamson et al., supra note 7, at 737.
274. Jerles, supra note 13, at 531U32.
275. See Fernandez Lynch, supra note 7, at 96U97; Jerles, supra note 13, at
521U22.
276. Cures for All: US Lawmakers Should Give Drug Firms the Confidence to
Test Cancer Therapies in Children, supra note 18, at 466.
277. Allen, supra note 26; Cures for All: US Lawmakers Should Give Drug
Firms the Confidence to Test Cancer Therapies in Children, supra note 18, at 466.
278. KIDS V CANCER, supra note 5.
279. Allen, supra note 26.
280. Id.
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No childhood should be interrupted by a struggle for
survival, but cancer tragically puts far too many kids in Maryland
and across the country in a battle for their lives. Researchers at
institutions like the National Institutes of Health have made
important progress on cancer research, and our laws need to reflect
this. House passage of this legislation brings us an important step
closer to updating statutes around drug development to reflect
recent advancements to research, which will help save children
and their families from the misery of this horrific disease.281
The passage of RACE would provide many new treatments for
pediatric cancer patients, leading to many more birthdays all while giving
families hope for a successful RACE to a cure.282
281. Press Release, Michael Bennet, Senator Bennet, Rubio, Van Hollen,
Gardner Applaud House Passage of RACE for Children Act (July 12, 2017) (on file with
author).
282. KIDS V CANCER, supra note 5. The author would like to add that since the
writing of this Comment, the RACE for Children Act has been signed into law as Title V of
the FDA Reauthorization Act, amending the Pediatric Research Equity Act, otherwise known
as PREA. Hopefully this leads to waiving the checkered flag, successfully completing the
RACE to a cure.
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